Akebia Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
We currently lease approximately 65,167 square feet of office, storage and laboratory space in Cambridge, Massachusetts, which is our corporate headquarters. Excluding renewal options, the lease for our Cambridge, Massachusetts office and storage space expires on September 11, 2026 and the lease for our laboratory space expires on January 31, 2025. In the third quarter of 2022, as a result of the reductions in our workforce and our transition to primarily hybrid and remote work schedules, we ceased using two-thirds of the office space, and began to market up to 59,216 square feet of furnished office space for sublease. We believe our existing facilities are adequate to meet our operational needs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.